Clinical Trials Logo

Clinical Trial Summary

This study will distribute videos of health professionals encouraging Covid-19 vaccination to a large sample of Facebook users, and will test the most effective ways to maximize diffusion of this vaccine-related content to increase vaccination rates. The study sample will be U.S. states where vaccination rates remained low in fall 2021. The experimental design is an RCT with 4 groups, randomized at the county level: 1) a control group which receives no intervention, 2) a treatment group in which Facebook users receive ads which include videos of health professionals telling them to get vaccinated, 3) a treatment group in which Facebook users receive ads which include videos of health professionals encouraging them to help their friends to get vaccinated, and 4) a treatment group in which Facebook users receive ads which include videos of health professionals encouraging them to get their most influential friends to help their friends get vaccinated. In treatments 3 and 4, participants will have the option to sign up to be a "vaccine ambassador," in which case they will get notifications when the study team posts new vaccine-related content, and will receive reminders about encouraging their friends to be vaccinated. The vaccine ambassadors will also be entered into a lottery to win prizes. The study team is building a website to host the videos of health professionals which answer common questions about Covid-19 vaccination. The investigators will measure engagement with the vaccine-related content as well as assess effects on vaccination rates at the county level.

Clinical Trial Description

The study will have three treatment arms and a control group. Each of the treatments will be randomized at the county level and will be initiated through a Facebook ad campaign. Experimental Sample: The experimental sample includes all states where less than 60% of the total population had received a first dose of Covid-19 vaccine by October 21, 2021. There are 1402 counties in the 19 states satisfying those criteria (Alabama, Alaska, Arkansas, Georgia, Idaho, Iowa, Indiana, Louisiana, Michigan, Mississippi, Missouri, Montana, North Dakota, Ohio, Oklahoma, South Carolina, Tennessee, West Virginia, Wyoming). Excluding the five counties with missing data, there are 1,397 counties in the experiment, of which there are 468 counties in the control group, 310 counties in T1 ("direct" messaging) treatment, 309 counties in T2 ("friends" messaging), and 310 counties in T3 ("gossips" messaging). The following procedures will be used: - Treatment Group 1 ("Direct" messaging): The investigators will conduct a Facebook ad campaign to show content about COVID-19 vaccination to a large number of Facebook users. Facebook will allocate ad credits across users in treatment areas. The ads will be displayed twice per week for 3-4 weeks. Like for any Facebook ad, individuals can choose to whether or not to watch the video and can close the ad at any time. If individuals wish, they can also share any of the content with others. The videos shown in the ads will be hosted on our project Facebook page "Doctors for Coronavirus Prevention." As in previous projects by the investigators, a health professional (normally wearing a white coat or scrubs) will read very short scripts directly onto the camera (see eg. for an example). - Treatment Group 2 ("Friends" messaging): For this group, the Facebook ad campaign will recruit individuals to become "vaccine ambassadors" to help spread the word about vaccination to their friends, families and communities. Recruitment ads will be disseminated in a similar manner to the content in T1. Individuals will be able to share the ad with others. Individuals interested in learning more can click through a link in the ad to the vaccine ambassador webpage. Participants can consume or share any of the information on the webpage. Interested individuals can also enroll formally as vaccine ambassadors. They can share their contact information with the study to a) be entered into prize lotteries, b) receive reminders to share content with others, c) be contacted in the future for possible follow-up surveys. They will be asked to give their informed consent at this time and will be screened based on whether they live in a treated county and whether they are 18 years or older. - Treatment Group 3 ("Gossips" messaging): This treatment looks the same as Treatment Group 2, except the recruitment ads will differ slightly. If the individual clicks through to learn more about vaccine ambassadors, they will also be reminded to share the invitation with people they know who are often the source of important news or information. - Control: individuals in these counties will receive no intervention and will never be contacted by members of the study team. Treatment and control status at the county level will be merged with aggregated and de-identified datasets to measure COVID vaccinations, COVID symptoms, and cases, and engagement with the vaccine ambassador content. The study team will create a series of websites with materials that the vaccine ambassadors can share with friends, family and others in their communities. This same content will be disseminated through sponsored Facebook ads in T1. On the website, the framing of the vaccine-related videos with either a "fact" or "myth" frame will be randomized. The purpose is to study which framing is more effective at engaging users. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05182554
Study type Interventional
Source Massachusetts Institute of Technology
Contact Lisa Ho, PhD Student
Phone 5106505455
Email [email protected]
Status Recruiting
Phase N/A
Start date December 22, 2021
Completion date June 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05197634 - The Impact of Covid-19 Pandemic On The Children With Autism Spectrum Disorder
Active, not recruiting NCT05125874 - Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization N/A
Recruiting NCT05062681 - RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow Phase 4
Completed NCT04697030 - Burnout Among Adolescent Population During Covid-19 Lockdown in Pakistan
Recruiting NCT05123573 - Self-Perceived in Medical Students Undergoing Distance Learning
Completed NCT04674644 - Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales N/A
Active, not recruiting NCT05098600 - The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
Recruiting NCT05096832 - Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study Phase 3
Not yet recruiting NCT05144139 - A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above Phase 1/Phase 2
Recruiting NCT05212870 - Investıgatıon Of The Effect Of The Pandemıc Process In Indıvıduals Wıth Chronıc Low Back And Neck Paın
Completed NCT05148676 - Residual Symptoms and the Quality of Life in Individuals Recovered From COVID-19 Infection: A Survey From Pakistan
Completed NCT04426266 - Psychological Effects of the COVID-19 Pandemic on the Hungarian Adult Population
Active, not recruiting NCT04842734 - Comparison of the Effect of Online Physical Exercise and Computerized Cognitive Stimulation in Patients With Alzheimer's Disease During the Covid-19 Pandemic N/A
Recruiting NCT05197452 - Increasing COVID-19 Testing in Chicago's African American Testing Desserts N/A
Recruiting NCT04474444 - Ambulance Calls for Substance Use and Alcohol in a Pandemic (ASAP)
Completed NCT05122208 - Famotidine in Covid-19 Intensive Care Unit
Active, not recruiting NCT05178251 - Impact of SARS-Cov2 Pandemic on Severity of Perioperative Complications in Patients Undergoing Appendectomy
Recruiting NCT04789499 - Smell in Covid-19 and Efficacy of Nasal Theophylline Phase 2
Not yet recruiting NCT05118763 - Intranasal INNA-051 for Prevention of COVID-19 in Adults Phase 2
Completed NCT04477473 - Perceived Impact of the COVID-19 Pandemic on Medical Management and Symptoms in a High Risk Group